Eisenführ Speiser strengthens patent practice in the fields of chemistry, biochemistry and pharmacy at the Munich and Hamburg offices

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Eisenführ Speiser strengthens patent practice in the fields of chemistry, biochemistry and pharmacy at the Munich and Hamburg offices

Sponsored by

24EisenfuhrSpeiserGermany.png

The two partners Dr André Guder and Dr Martin Nohlen are moving from the renowned law firm Uexküll & Stolberg together with the associates Dr Hanna Pieper, Dr Nils Lindenmaier and Dr Johannes Heidemann.

Eisenführ Speiser is strengthening its team with five patent attorneys at both partner and associate level, thereby supplementing its capacities in the fields of chemistry, biochemistry and pharmaceuticals. The two partners Dr André Guder and Dr Martin Nohlen are moving from the renowned law firm Uexküll & Stolberg together with the associates Dr Hanna Pieper, Dr Nils Lindenmaier and Dr Johannes Heidemann and will be working at Eisenführ Speiser's Hamburg and Munich offices.

André Guder practises in the fields of life sciences, biotechnology, cosmetics, food technology and pharmacology. One focus of his work is strategic portfolio consulting as well as conducting patent prosecution, opposition and appeal proceedings. He also has special expertise in the field of supplementary protection certificates.

As a chemist, Martin Nohlen has a particular focus on polymer and catalyst technology, fine chemicals, oil and fuel additive technology, fuel cells, CO2 reduction technologies, pharmaceuticals and cosmetics. He is particularly active in opposition and appeal proceedings for clients from the Anglo-American region. André Guder and Martin Nohlen will continue their work at Eisenführ Speiser as partners at the Hamburg office with their team from 01 November 2024 / 01 January 2025.

Hanna Pieper, Nils Lindenmaier and Johannes Heidemann specialise in German and international patent grant proceedings, oppositions and nullity proceedings as well as the preparation of legal opinions in the fields of chemistry, pharmaceuticals and life sciences. They will work as associates at Eisenführ Speiser - Nils Lindenmaier at the Munich office, Hanna Pieper and Johannes Heidemann at the Hamburg office.

"We are delighted to be able to expand our partnership with the team of two renowned and experienced patent attorneys, Dr André Guder and Dr Martin Nohlen. This will enable us to meet the high demand in the technical fields of chemistry, biochemistry and pharmacy and to position ourselves very broadly in this very spectrum across all locations," say the managing directors of Eisenführ Speiser, Dr Lars Birken and Dr Julian Eberhardt.


About patent attorney André Guder:

9946.png

Dr André Guder
Patent Attorney,

European Patent Attorney,

Representative before the UPC,

Partner

Hamburg office

André Guder practises in the fields of life sciences, biotechnology, cosmetics, food technology and pharmacology. One focus of his work is strategic portfolio consulting as well as conducting patent grant, opposition and appeal proceedings. He also has special expertise in the field of supplementary protection certificates.

André Guder has been advising renowned companies such as Beiersdorf AG and Boehringer Ingelheim International GmbH on the development and management of their portfolios for many years. He also regularly represents national and international clients in opposition and appeal proceedings. For example, he represents the US company Amgen before the EPO in the defence of several patents relating to the manufacture of erythropoietin.

André Guder is regularly recommended in the Legal 500 Ranking as well as in the IAM Patent 1000 Ranking.

About patent attorney Martin Nohlen:

9946.png

Dr Martin Nohlen

Patent Attorney,

European Patent Attorney,

Representative before the UPC,

Partner

Hamburg office

As a chemist, Martin Nohlen has a particular focus on polymer and catalyst technology, fine chemicals, oil and fuel additive technology, fuel cells, CO2 reduction technologies, pharmaceuticals and cosmetics.

Martin Nohlen is particularly active in opposition and appeal proceedings for clients from the Anglo-American region and is therefore also familiar with the coordination of international patent disputes. In the past, he has been involved in disputes concerning the enforcement of US and EP patents in the field of catalysts for polymer production and additives for diesel fuels.

Martin Nohlen is recommended in the IAM Patent 1000 Rankings 2023 and 2024.

more from across site and SHARED ros bottom lb

More from across our site

Rebekah Gay discusses overcoming self-doubt, supporting the next generation of women lawyers, and how changing client demands are reshaping IP practice
New filing data suggests Germany's grip on UPC litigation remains strong, while Bardehle Pagenberg, Arnold Ruess, Hogan Lovells and Carpmaels notch up notable cases
In 27 years, KASS has expanded to seven countries in southeast Asia and is now eyeing further growth opportunities. Its CEO shares her perspective
Mine Güner discusses bridging law and business, taking the initiative, and why Taylor Swift helped put copyright on the map
Cindy Goh discusses why she launched Cheang & Ariff's IP department, the improving litigation environment in Malaysia and what to consider when using AI
Increased focus on adding patent litigation depth to the firm’s Dallas office was behind the boutique’s most recent hires
IPH's Canadian acquisitions are paying off on paper, but a couple of strong years may not be enough to show that the group's strategy has truly won over the market
Examiner statistics could help patent prosecution practitioners tailor strategies, turning an area of high variability into a potential competitive advantage
The England and Wales High Court’s ruling in Accord v Novartis may not rewrite the law on plausibility, but it does signal a pragmatic approach that could provide greater certainty for life sciences innovators
Firms with established sports relationships and specialised expertise are well positioned to capture the market’s expanded pool of IP work
Gift this article